AMERICAN JOINT COMMITTEE ON CANCER

美国联合委员会一直在从事一项临床研究项目，以 为所有解剖部位的癌症制定分期分类。在.期间 在过去的一年里，在对联合司法委员会今后的活动进行了大量思考之后， 以下计划已取得成果：1)完成分类，如进一步 需要做的工作是：骨骼、中枢神经系统、黑色素瘤和胃肠道恶性肿瘤； (2)为鼓励在最终结果报告中使用分级方法， 向期刊、图书馆、癌症登记处和医学会报告；3) 与在国家层面上进行癌症分期的团体合作，即， SEER、CCPDS、CICA、ACCC、ACOS和其他中央和医院注册机构，以 制定通用计算机代码；(4)进一步细化、宣传、分发和 鼓励使用特定地点的癌症数据收集表格；5)测试 分类的有效性，使用SEER和其他组的数据；6)至 评估生物标记物和其他对 对特定癌症及其预后进行分类，并确定其 相对重要性；7)评估相对重要性和成本 不同检测方法在临床前处理中的应用效果 分期和治疗后后续评估，以努力阻止 过度使用昂贵的检测，这些检测很少是阳性的，对 管理层。

The American Joint Committee has been engaged in a clinical research project to develop staging classifications for cancer of all anatomic sites. During the past year following considerable thought as to the future activities of the AJC, the following plan has resulted: 1) To complete classifications where further work is needed: bone, central nervous system, melanoma, and GU malignancies; (2) To encourage the use of classification for staging in end results reporting, reporting to journals, libraries, cancer registries, and medical societies; 3) To work with groups on a national level who are doing cancer staging, i.e., SEER, CCPDS, CICA, ACCC, ACOS, and other central and hospital registries, to develop a common computer code; (4) To further refine, publicize, distribute and encourage use of specific site cancer data collection forms; 5) To test the validity of the classifications, with data from SEER and other groups; 6) To evaluate biological markers and other factors which are important in classification of specific cancers and their prognoses, and to determine their relative importance; 7) To evaluate the relative importance and cost effectiveness of various tests and procedures utilized in pretreatment clinical staging and in posttreatment follow-up evaluations, in an effort to discourage over-utilization of expensive tests which are rarely positive and add little to management.